PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 28, 2026Diabetes Obesity and Metabolism4 citations

Safety of GLP ‐1 and Dual GLP ‐1/ GIP Receptor Agonists in Preconception, Pregnancy, and Lactation: A Systematic Review of Maternal, Fetal, and Neonatal Outcomes

View Full Paper
LÖLaşin ÖzbekESE Abu ShahRARama Al‐Shiab

Key Points

  • To evaluate the safety of GLP-1 and dual GLP-1/GIP receptor agonists during preconception, pregnancy, and lactation.
  • Conducted a systematic review of existing literature
  • Assessed maternal, fetal, and neonatal outcomes
  • Focused on GLP-1-based therapies in early pregnancy
  • No consistent evidence of increased maternal risk was found
  • Fetal and neonatal risks appear minimal with early exposure
  • Limited data exists on the safety of continued use throughout pregnancy

Abstract

Current evidence suggests that preconceptional or early-pregnancy exposure to GLP-1-based therapies is not consistently associated with increased maternal, fetal, or neonatal risk, although data on continued use throughout gestation remain limited.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Özbek et al. (2026) studied this question.

synapsesocial.com/papers/69c771348bbfbc51511e117fhttps://doi.org/10.1111/dom.70699
Ask AI
Helpful
Bookmark
Share
View Full Paper